Acceleron Pharma Inc

Acceleron Pharma — Investor Presentation (January 2015)

68 slides from Acceleron Pharma's investor presentation, Jan 12, 2015

  1. Slide 1: Corporate Overview January 2015

    Page 0 Corporate Overview January 2015

  2. Slide 2: Forward-Looking Statements

    Page 1 Acceleron Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our bu

  3. Slide 3: The Mission of Acceleron Pharma

    Page 2 The Mission of Acceleron Pharma Acceleron will be a leader in the discovery, development and commercialization of therapeutics based on the body’s ability to regulate the growth and repair of its cells and tissues. By leveraging this powerful biology, Acceleron seeks to provide medicines that

  4. Slide 4: Leader in protein therapeutics that regulate cellular growth and repair

    Page 3 Acceleron is a leader in discovering and developing protein therapeutics that regulate cellular growth and repair Tissue Growth and Repair is Central to Human Disease and Health • Disease is often caused by either • Failure of cells or tissues to properly grow, differentiate and maintain the

  5. Slide 5: Leader in Cell and Tissue Growth and Repair

    Page 4 Red Blood Cells Acceleron – Leader in Cell and Tissue Growth and Repair Red Blood Cells Bone Vasculature Increases number of red blood cells Luspatercept Sotatercept Dalantercept Increases bone mass and strength, and RBC number Inhibits blood vessel growth Muscle ACE-083 Increases muscle mass

  6. Slide 6: One of the Industry's Most Robust Pipelines of Internally Discovered Protein Therapeutics

    Page 5 Acceleron -- One of the Industry’s Most Robust Pipelines of Internally Discovered Protein Therapeutics Creating Near-term and Sustainable Value Product Indication Development Stage Commercial Rights Luspatercept β-Thalassemia Phase 3 to start in 2015 • Co-development • North American co-promo

  7. Slide 7: Highly Productive 2014 Sets Stage for 2015 Value Creation

    Page 6 Highly Productive 2014 Sets Stage for 2015 Value Creation  Demonstrated phase 3-enabling data in MDS  Demonstrated phase 3-enabling data in beta-thalassemia  Demonstrated proof-of-concept on bone density and vascular calcification in ESRD patients  Advanced exploratory phase 2 studies in

  8. Slide 8: Hematology Franchise: Luspatercept and Sotatercept

    Page 7 Hematology Franchise Luspatercept and Sotatercept

  9. Slide 9: Myelodysplastic Syndromes (MDS)

    Page 8 Myelodysplastic Syndromes (MDS)

  10. Slide 10: MDS Opportunity: Develop Better Treatment for Lower Risk Patients

    Page 9 MDS Opportunity: Develop Better Treatment for Lower Risk Patients In the U.S., recombinant erythropoietin sales in MDS are approximately $600 million EPO MDS (125,000 patients in US/EU-G5)) Low Risk (70,000 patients US/EU-G5) High Risk (55K patients) RBC transfusions (± iron chelation) Revlim

  11. Slide 11: MDS Program Highlights

    Page 10 MDS Program Highlights • Luspatercept data in Myelodysplastic Syndromes selected for "Best of ASH" by the American Society of Hematology • Preliminary Phase 2 results demonstrated – Increases in hemoglobin levels – Decreases in transfusion burden with patients becoming transfusion independen

  12. Slide 12: MDS Development Plan: Initiate Phase 3 in 2015

    Page 11 MDS Development Plan: Initiate Phase 3 in 2015 Q1 Q2 Q3 Q4 Confirm dose-titration in expansion cohort (n=30) Health Authority meetings re: Phase 3 Initiate Phase 3 trials 2015 Q3 Q4 2014 Completed dose escalation cohorts (n=27)

  13. Slide 13: MDS Phase 3 Development Opportunities

    Page 12 MDS Phase 3 Development Opportunities EPO Low Risk MDS (70,000 patients US/EU-G5) Revlimid® Vidaza® Dacogen® 2nd Line Opportunity: ESA experienced patients • Endpoint: Incidence of RBC Transfusions • Randomized vs. best supportive care 1st Line Opportunity: ESA naïve patients • Endpoint: Inc

  14. Slide 14: B-thalassemia

    B-thalassemia =! =" = ACCELERON

  15. Slide 15: Beta-Thalassemia Opportunity

    Page 14 Beta-Thalassemia Opportunity: Develop Treatment for Both Non-Transfusion and Transfusion Dependent Patients Beta-Thalassemia (40,000 patients in US/EU) Non-Transfusion Dependent (20,000 patients US/EU) Transfusion Dependent (20,000 patients US/EU) RBC transfusions (iron chelation used to man

  16. Slide 16: Beta-Thalassemia Program Highlights

    Page 15 Beta-Thalassemia Program Highlights • Preliminary Phase 2 results demonstrated – Activity in both non-transfusion and transfusion dependent patients that met/exceeded endpoints expected to be used in phase 3 trials • Increases in hemoglobin levels • Decreases in transfusion burden • Reductio

  17. Slide 17: Beta-Thalassemia Development Plan: Initiate Phase 3 in 2015

    Page 16 Beta-Thalassemia Development Plan: Initiate Phase 3 in 2015 Q1 Q2 Q3 Q4 Confirm dose-titration in expansion cohort (n=30) Health Authority meetings re: Phase 3 Initiate Phase 3 trials 2015 Q3 Q4 2014 Completed dose escalation cohorts (n=30)

  18. Slide 18: Beta-Thalassemia Phase 3 Program

    Page 17 Beta-Thalassemia Phase 3 Program Beta-Thalassemia (40K patients in US/EU) Non-Transfusion Dependent (20,000 patients US/EU) Transfusion Dependent (20,000 patients US/EU) Phase 3 – NTD Patients • Endpoints • Primary: hemoglobin increase ≥ 1.5 g/dL • Secondary: decreases in iron overload • Ran

  19. Slide 19: Sotatercept Opportunity in Chronic Kidney Disease

    Page 18 Sotatercept Opportunity in Chronic Kidney Disease

  20. Slide 20: ESRD Opportunity: Novel Drug for Bone Loss and Vascular Calcification

    Page 19 ESRD Opportunity: Develop Fundamentally Novel Drug to Treat Bone Loss and Vascular Calcification ESRD patients on hemodialysis (700,000 patients in US/EU) Vascular Calcification Bone Loss Epidemiology Current Treatments Therapeutic Goal • Increase bone mineral density • Reduce vascular calci

  21. Slide 21: ESRD Program Highlights

    Page 20 ESRD Program Highlights • Preliminary sotatercept Phase 2 results demonstrated – Increases in cortical bone mineral density – Reductions in vascular calcification – Increases in hemoglobin levels • 2015 program goals – Complete ongoing Phase 2a study – Compete dose finding stage of ongoing P

  22. Slide 22: ESRD Development Plan

    Page 21 ESRD Development Plan Q1 Q2 Q3 Q4 Phase 2b - dose finding stage (n=~60) 2015 Q3 Q4 2014 Phase 2a study (n=~48) Phase 2b - randomized, placebo-controlled stage (n=230)

  23. Slide 23: Muscle Franchise: ACE-083

    Page 22 Muscle Franchise ACE-083

  24. Slide 24: ACE-083 Doubles Muscle Mass in Injected Muscle After One Month

    Page 23 ACE-083 Doubles Muscle Mass Selectively in Injected Muscle After One Month of Treatment 0.0000 0.0020 0.0040 0.0060 0.0080 0.0100 0.0120 0.0140 Left Right Gastroc Ga st roc W eig h t N o rm ali ze d t o B o d y W eig h t PBS ACE-083 1μg ACE-083 3μg ACE-083 10μg ACE-083 30μg ACE-083 100μg ACE

  25. Slide 25: MRI Imaging of Muscle and Fat to Demonstrate Changes

    Page 24 MRI Imaging of Muscle and Intramuscular and Subcutaneous Fat Will be Used to Demonstrate Changes in Muscle Size and Composition SC Fat Muscle IM Fat Grey = Muscle Pink = SC fat Green = IM fat

  26. Slide 26: Potential Clinical Indications For ACE-083

    Page 25 Affected Muscle Groups in Muscle Wasting Diseases Potential Clinical Indications For ACE-083 Facioscapulohumeral Muscular Dystrophy (16,000 patients – US) Inclusion Body Myositis (11,000 patients – US) Muscular Dystrophy Association USA

  27. Slide 27: ACE-083 Development Plan

    Page 26 ACE-083 Development Plan: Initiate Phase 2 Studies in 2015 Q1 Q2 Q3 Q4 2015 Q3 Q4 2014 Phase 1 study (n=40) Phase 2 study

  28. Slide 28: Dalantercept

    Page 27 Dalantercept Novel anti-angiogenic agent based on the Activin Receptor-Like Kinase 1 (ALK1)

  29. Slide 29: Dalantercept Opportunity in RCC and HCC

    Page 28 Dalantercept Opportunity in RCC and HCC Renal Cell Carcinoma (65,000 new patients/year in US) Chemo, TACE Epidemiology Current Treatments VEGFR TKIs mTOR inhibitors Hepatocellular Carcinoma (31,000 new patients/year in US) • More than 70% of all RCC patients currently receive an anti-VEGF dr

  30. Slide 30: Dalantercept + anti-VEGF Development Plan

    Page 29 Dalantercept + anti-VEGF Development Plan Q1 Q2 Q3 Q4 Randomized, placebo-controlled stage (n=130) RCC (+ axitinib) HCC (+ sorafenib) HCC(+ sorafenib) 2015 Q3 Q4 2014 RCC (+ axitinib) Completed dose escalation cohorts (n=29) Dose escalation cohorts Dose expansion cohort

  31. Slide 31: Financial Highlights

    Page 30 Financial Highlights • Cash and cash equivalents at the end of September 2014 were $189 million • Cash and cash equivalents expected to provide the Company funding for three years into the second half of 2017

  32. Slide 32: Anticipated Data Presentations in 2015

    Page 31 Anticipated Data Presentations in 2015 Program Indication Date / Meeting Dalantercept RCC February; ASCO-GU Luspatercept MDS April; MDS Int’l Symposium June; EHA December; ASH Beta-thalassemia June; EHA December; ASH ACE-083 Muscle October; World Muscle Society Sotatercept ESRD May; ERA-EDTA

  33. Slide 33: Poised for Significant Value Creation in 2015

    Page 32 Poised for Significant Value Creation in 2015  Complete phase 2 studies in MDS and beta-thalassemia  Finalize phase 3 development plans with health authorities for MDS and beta-thalassemia  Initiate phase 3 clinical trials in MDS  Initiate phase 3 clinical trials in beta-thalassemia  In

  34. Slide 34: Acceleron's 2020 Vision

    Page 33 • Two Phase 3 studies • Six Phase 2 studies • One Phase 1 study • 4 protein therapeutics in clinical trials • Numerous preclinical programs • Approvals in up to 5 indications • Multiple Phase 3 studies • 8 protein therapeutics in clinical trials • Sales and marketing organization in U.S. • C

  35. Slide 35: Additional Information

    Page 34 Additional Information

  36. Slide 36: Myelodysplastic Syndromes (MDS) Presented at ASH 2014

    Page 35 Myelodysplastic Syndromes (MDS) Presented at ASH 2014

  37. Slide 37: Luspatercept PACE-MDS Study Design

    Page 36 Luspatercept PACE-MDS Study Design Cohort 7 1.75 mg/kg (N=3) Cohort 5 1.0 mg/kg (N=3) Cohort 6 1.33 mg/kg (N=6) Cohort 1 0.125 mg/kg (N=3) Cohort 2 0.25 mg/kg (N=3) Cohort 3 0.5 mg/kg (N=3) Cohort 4 0.75 mg/kg (N=6) 3 Months Treatment Expansion Cohort Individually titrated dose (N=30) Data a

  38. Slide 38: Baseline Characteristics

    Page 37 Baseline Characteristics All Patients N = 26 Age, yr, median (range) 71 (27-88) Sex, males (%) 13 (50%) Prior ESA treatment, n (%) 14 (54%) Prior lenalidomide treatment, n (%) 5 (19%) Low Transfusion Burden (LTB) N = 7 (27%) Hemoglobin, g/dL, median (range) 9.1 (8.3-9.7) Units RBC/8 weeks, m

  39. Slide 39: Pharmacokinetic and Safety Summary

    Page 38 Pharmacokinetic and Safety Summary Pharmacokinetics  Dose-dependent increase in Cmax and area under curve (AUC)  Mean half-life (t½) is approximately 14 days, supporting Q3W dosing Safety  No drug-related serious adverse events (AEs)  One possibly related grade 3 AE of blast cell count i

  40. Slide 40: Luspatercept Increased Hemoglobin and Reduced Transfusions in Lower Risk MDS

    Page 39 Patient Subgroup 0.125-0.5 mg/kg (N=9) n (%) 0.75-1.75 mg/kg (N=17) n (%) LTB patients (N=7) 0/2 (0%) 2/5 (40%) HTB patients (N=19) 2/7 (29%) 5/12 (42%) All patients (N=26) 2/9 (22%) 7/17 (41%) HI-E (IWG): LTB: Hemoglobin increase ≥1.5 g/dL for ≥8 weeks HTB: Reduction of ≥4 units RBCs transf

  41. Slide 41: Luspatercept Produced Dose Dependent Increases in LTB Patients

    Page 40 Data as of 03 Oct 2014 LTB, low transfusion burden M ean ( SD ) M ax. C h an ge in H emogl o b in ( g/ d L) 0.8 1.0 2.2 3.5 0.0 1.0 2.0 3.0 4.0 0.125 (n=1) 0.25 (n=1) 0.75 (n=3) 1.75 (n=2) Dose Group (mg/kg) Luspatercept Produced Dose Dependent Increases in LTB Patients Luspatercept MDS Phas

  42. Slide 42: Luspatercept Increased and Maintained Hemoglobin in LTB Patients

    Page 41 Response Criteria 0.125-0.5 mg/kg N=2 n (%) 0.75-1.75 mg/kg N=5 n (%) Hemoglobin increase ≥1.5 g/dL for ≥2 weeks 0 4 (80%) Hemoglobin increase ≥1.5 g/dL for ≥8 weeks (HI-E) 0 2 (40%) • All 5 patients at the higher dose levels had prior ESA treatment • No patients received prior lenalidomide

  43. Slide 43: Luspatercept Activity in a LTB Patient

    Page 42 Hemoglobin ( g /d L) Weeks -- 0.56 mg/kg (dose reduced by 25%) Data as of 03 Oct 2014 LTB, low transfusion burden 2 0 1 2 3 4 5 6 7 8 6 7 8 9 10 11 12 13 -8 -6 -3 BL 3 6 9 12 16 20 24 Units Transfused Hemoglobin Follow-up Period Dose held for Hb >12 g/dL -- 0.75 mg/kg (starting dose) 78 year

  44. Slide 44: Luspatercept Reduced Transfusions in HTB Patients

    Page 43 HTB, high transfusion burden • 9/19 (47%) of patients received prior ESA treatment • 5/19 (26%) of patients received prior lenalidomide treatment RBC Transfusion Reduction over 8 Weeks 0.125-0.5 mg/kg N=7 n (%) 0.75-1.75 mg/kg N=12 n (%) ≥4 Units or ≥50% 3 (43%) 5 (42%) ≥4 Units (HI-E) 2 (29

  45. Slide 45: Luspatercept Activity in a HTB Patient

    Page 44 Weeks Data as of 03 Oct 2014 HTB, high transfusion burden Hemoglobin ( g /d L) Follow-up Period 2 2 0 2 4 6 8 10 12 5 6 7 8 9 10 11 -3 BL 3 6 9 12 16 20 24 Units Transfused Hemoglobin 0.75 mg/kg (starting dose) 71 year old female RCMD-RS Failed LEN, EPO Luspatercept Activity in a HTB Patient

  46. Slide 46: Response Rates by Ring Sideroblast Morphology, SF3B1 Mutation

    Page 45 Data as of 03 Oct 2014 Baseline Status Response Rate (HI-E) n (%) All Patients (N=17) 7 (41%) Ring Sideroblasts RS ≥15% (N=13) 7 (54%) RS <15% (N=4) 0 (0%) Response Rate at Higher Dose Levels (0.75-1.75 mg/kg) * All 9 patients with SF3B1 mutation present had RS ≥15% ** Includes all 3 patient

  47. Slide 47: β-thalassemia Presented at ASH 2014

    Page 46 β-thalassemia Presented at ASH 2014

  48. Slide 48: β-thalassemia: Rare Hematologic Disease with Substantial Unmet Medical Need

    Page 47 Bone deformity, fractures and bone pain Iron overload, liver and heart failure Enlarged spleen, blood clots and ulcerations Chronic anemia β-thalassemia: Rare Hematologic Disease with Substantial Unmet Medical Need Beta-Thalassemia is red blood cell (RBC) disease Substantial unmet medical ne

  49. Slide 49: Study Overview: Luspatercept β-Thalassemia Phase 2 Trial

    Page 48 Study Overview Luspatercept -Thalassemia Phase 2 Clinical Trial NCT01749540, EudraCT 2012-002499-15 • A phase 2, multicenter, open-label, dose escalation study in adults with β-thalassemia • Primary efficacy endpoints: • Non-transfusion dependent (NTD)*  Hb increase of ≥ 1.5 g/dL for ≥ 2 w

  50. Slide 50: Study Design: Luspatercept β-Thalassemia Phase 2 Trial

    Page 49 Study Design Luspatercept -Thalassemia Phase 2 Clinical Trial Cohort 5 1.0 mg/kg (N=6) Cohort 1 0.2 mg/kg (N=6) Cohort 2 0.4 mg/kg (N=6) Cohort 3 0.6 mg/kg (N=6) Cohort 4 0.8 mg/kg (N=6) 3 Months Treatment Completed Data from completed cohorts presented Cohort 6 1.25 mg/kg (N=6) Expansion C

  51. Slide 51: Baseline Characteristics

    Page 50 Baseline Characteristics Luspatercept -Thalassemia Phase 2 Clinical Trial All Patients N=30 Age, yr, median (range) 34.5 (20-57) Sex, male (%) 16 (53%) Splenectomy (%) 25 (83%) Non-Transfusion Dependent (NTD) N= 23 (77%) Hemoglobin, g/dL, mean ± SD 8.3 ± 0.9 Transfusion Dependent (TD) N=7 (

  52. Slide 52: Safety Summary

    Page 51 Safety Summary Luspatercept -Thalassemia Phase 2 Clinical Trial • No related serious adverse events – 1 grade 3 dose-limiting toxicity (worsening lumbar spine bone pain) • 3 patients discontinued early associated with an AE – 1 each with occipital headache, ankle pain, and back pain Data as

  53. Slide 53: Luspatercept Increased Hemoglobin and Reduced Transfusions

    Page 52 Luspatercept Increased Hemoglobin and Reduced Transfusions Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 75% of patients treated with 0.8-1.0 mg/kg met the primary endpoint for efficacy 0.2-0.6 mg/kg (N=18) n (%) 0.8-1.0 mg/kg (N=12) n (%) NTD Patients (N=23): Hemo

  54. Slide 54: Reduced Transfusion Burden in TD Patients

    Page 53 Reduced Transfusion Burden in TD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial -100 -80 -60 -40 -20 0 -79% -67% -70% -75% -63% -67% -100% • 7/7 (100%) patients had >60% reduction in transfusion burden over 12 weeks • Includes 2 patients with β0β0 genotype (79%, 75% reduction) TD

  55. Slide 55: Maximum Hemoglobin Increase in NTD Patients

    Page 54 NTD, Non-transfusion dependent Maximum Hemoglobin Increase in NTD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014

  56. Slide 56: NTD Responder Hemoglobin

    Page 55 NTD Responder Hemoglobin Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 NTD, Non-transfusion dependent He m og lo bi n (g /d L) Weeks 0 1 2 3 4 5 6 7 8 6 7 8 9 10 11 -3 BL 3 6 9 12 16 20 Hemoglobin 0.8 mg/kg 24 year old male Splenectomized Follow-up Period

  57. Slide 57: Liver Iron Concentration in NTD Patients

    Page 56 Liver Iron Concentration (LIC by MRI) in NTD Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Data as of 10 Oct 2014 Baseline LIC ≥ 5 mg/g dry weight (dw) (n=12) • 8/12 patients had a decrease of ≥1 mg/g dw -5 -4 -3 -2 -1 0 1 2 3 On iron chelator No iron chelator C h an ge f ro m B

  58. Slide 58: Healing of Leg Ulcers in Patients

    Page 57 Healing of Leg Ulcers in 2 of 2 Patients Luspatercept -Thalassemia Phase 2 Clinical Trial Pre-Treatment After 6 Weeks Pre-Treatment After 4 Weeks After 18 Weeks TD patient treated at 1.0 mg/kg NTD patient treated at 0.4 mg/kg NTD, Non-transfusion dependent TD, Transfusion dependent Data as

  59. Slide 59: Sotatercept Opportunity in Chronic Kidney Disease

    Page 58 Sotatercept Opportunity in Chronic Kidney Disease

  60. Slide 60: Chronic Kidney Disease Mineral and Bone Disorder

    Page 59 Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) End-Stage Renal Disease Anemia Nearly all end-stage renal disease patients on dialysis suffer from anemia and mineral and bone disorder Mineral and Bone Disorder Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism Abno

  61. Slide 61: Sotatercept Improved Bone Metabolism

    Page 60 • Unlike age-related osteoporosis, in CKD-related bone disease there can be – Increase in trabecular bone mass and a decrease in cortical bone mass • Sotatercept data presented at the 2014 ASN Kidney Week showed dose-dependent – Decreases in trabecular bone mass – Increases in cortical bone

  62. Slide 62: Vascular Calcification in ESRD Patients

    Page 61 • Two types of vascular calcification - intimal (atherosclerotic) and medial • Both associated with osteoblastic transition of vascular smooth muscle cells • Medial calcification more common in ESRD patients • Vascular calcification is the strongest measure in cardiovascular risk prediction

  63. Slide 63: Sotatercept Substantially Slowed Vascular Calcification

    Page 62 Sotatercept Substantially Slowed Vascular Calcification Sotatercept Phase 2 Clinical Trial in ESRD Patients 58.4% 24.9% 17.3% 3.4% 0 10 20 30 40 50 60 70 Placebo 0.3 mg/kg 0.5 mg/kg 0.7 mg/kg Change in Agatston Score Over 8 Months Agatston score is a standard measure of vasculature calcifica

  64. Slide 64: Dalantercept (ACE-041)

    Page 63 Dalantercept (ACE-041) Novel anti-angiogenic agent based on the Activin Receptor-Like Kinase 1 (ALK1)

  65. Slide 65: BMP9/ALK1 Pathway: Novel Target for Angiogenesis

    Page 64 BMP9/ALK1 Pathway: Novel Target for Angiogenesis • ALK1 is selectively expressed on vascular and lymphatic endothelial cells • In mice, homozygous deletion of ALK1 (-/-) results in severe vascular defects and embryonic lethality • Patients with hereditary hemorrhagic telangiectasia (HHT-2) h

  66. Slide 66: Dalantercept Combination Development Strategy

    Page 65 Dalantercept Combination Development Strategy: Inhibit Two Key Steps in Angiogenesis to Improve Clinical Outcomes Concept: Inhibit sequential steps in pathway to augment angiogenic blockade Proliferation VEGF Receptor Maturation ALK1 Receptor Mature blood vessel supporting tumor growth

  67. Slide 67: Positive Results from Part 1 RCC Ph2 Study

    Page 66 Positive Results from Part 1 RCC Ph2 Study dalantercept + axitinib (presented at ASCO 2014) • Dalantercept combination therapy was well-tolerated and no dose-limiting toxicities were observed in the dose escalation cohorts • Encouraging preliminary efficacy of dalantercept: – Combination ach

  68. Slide 68: Dalantercept Vision: Improve and Extend Response Rates

    Page 67 IntrinsIQ (Diag Drug LOT Yearly Kidney Cancer April 2014), Evaluate Pharma By combining with established practice of using anti-VEGF therapies, dalantercept can quickly access a large segment of both the RCC and HCC markets Dalantercept Vision: Improve and Extend Response Rates • Worldwide s

Acceleron Pharma — Investor Presentation (January 2015) on 6ix